Testing a Cancer-Fighting Virus With a PD-1 Drug for High-Grade Glioma That Came Back
Official title: A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This trial is testing whether a virus made to attack tumors, given with a PD-1 drug, can help people whose high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary has come back.
Read our full plain-language summary
What the trial team says
A single-arm clinical study on the efficacy and safety of the novel oncolytic virus Ad-TD-nsIL12 combined with PD-1 inhibitors in the treatment of recurrent high-grade glioma
Key facts
- Registry number
- NCT07472790
- Stage of testing
- Phase 1
- Conditions studied
- High-grade Glioma
Where it is running
This trial lists 1 site.
-
Chaoyang District
- Sanbo Brain Hospital, Capital Medical University (Beijing)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.